Celgene has backed a funding round for oncology treatment developer Sapience Therapeutics that also included corporate-backed technology advisory firm TaiAn Technologies.
US-based biotechnology company Sapience Therapeutics raised $22.5m yesterday in a series A round led by venture capital firm Eshelman Ventures that featured healthcare company Celgene.
The round also involved Healthlink Capital and TaiAn Technologies, a biotechnology advisory and commercialisation firm backed by industrial corporates including China Steel, Taiwan Fertilizer and Oriental Union Chemical.
Sapience, a spinout of Columbia University, is developing therapies for conditions with a significant unmet medical need, focusing particularly on high mortality cancers.
The company’s lead drug…
